Joao Andrade, chief executive at stem cells specialist WideCells Group (LON:WDC) talks to Proactive Investors about the definitive agreement the group signed in the UK with Biovault Technical, which will facilitate the first sales of CellPlan to Biovault’s customer base.
"We are now very excited because we awere now able to reach an agreement with Biovault. Biovault is one of the cord blood banks in the world operating to the highest quality standards and that's really the type of company we would like to start working with," he says. "This is a very exciting time for us," he adds.
Discussing the commercial strategy for CellPlan sales he says: "we are expecting the uptake to be increasing as the year develops."
"This type of product is able to generate revenue for a number years."